Diagnosis value of CD117 and PDGFRA, alone or in combination DOG1, as biomarkers for gastrointestinal stromal tumors

Chunwei Xu, Hongyan Han, Jingjing Wang, Bo Zhang, Yun Shao, Liying Zhang, Huaitao Wang, Haiyan Wang, Yongfang Wu, Xiaobing Li, Ruiming Li, Yuwang Tian


Background: To explore the diagnostic values of CD117 and PDGFRA protein expressions, used alone or in combination with DOG1 protein, for gastrointestinal stromal tumors (GIST).
Methods: The CD117, PDGFRA and DOG1 protein expressions in 99 GIST specimens and 25 non-GIST specimens were retrospectively determined, and the potential correlations were analyzed.
Results: The positive rates of CD117, PDGFRA, and DOG1 expressions were 93.94% (93/99), 53.54% (53/99), and 90.91% (90/99) in GIST group and 4.00% (1/25), 4.00% (1/25), and 12.00% (3/25) in non-GIST group (all P<0.05). The expressions of CD117, PDGFRA, and DOG1 had no significant correlation with clinicopathological parameters including gender, age, tumor diameter, tumor location, histotype, and risk degree (all P>0.05). The sensitivities of CD117, PDGFRA, DOG1, CD117 + DOG1, PDGFRA + DOG1, and CD117 + PDGFRA + DOG1 were 0.989, 0.981, 0.968, 0.960, 0.933, and 0.961 in judging GIST, respectively, and the specificities were 0.800, 0.343, 0.710, 0.840, 0.947, and 0.955, respectively. The areas under the ROC curve (AUC) in these six groups were 0.945, 0.748, 0.895, 0.895, 0.840, and 0.975, respectively.
Conclusions: The populations that may benefit more from the detection of CD117, PDGFRA, and DOG1 protein expression for GIST need to be further identified. Detection of CD117 and PDGFRA protein, alone or in combination with DOG1, may increase the accuracy of GIST diagnosis.